Table 4.
Mean persistence with biologic and JAK inhibitor treatment.
| Treatment | UC | CD | ||
|---|---|---|---|---|
| First line (n = 587) | Second line (n = 55) | First line (n = 417) | Second line (n = 70) | |
| Infliximab | 26.6 ± 35.4; n = 256 | 57.7 ± 0.8; n = 2 | 31.2 ± 29.5; n = 154 | 28.5 ± 30.8; n = 7 |
| Infliximab biosimilars | ||||
| CT-P13 | 16.6 ± 9.7; n = 62 | 12.5 ± 3.3; n = 5 | 20.3 ± 12.4; n = 47 | 10.9 ± 11.2; n = 2 |
| SB2 | 24.8 ± 20.5; n = 11 | 5.1 ± 0.8; n = 2 | 10.8 ± 4.1; n = 5 | 29.3 ± 29.2; n = 2 |
| Adalimumab | 21.2 ± 19.5; n = 189 | 64.6 ± 87.4; n = 8 | 26.7 ± 30.4; n = 153 | 27.2 ± 34.5; n = 10 |
| Adalimumab biosimilars | ||||
| ABP 501 | 8.6 ± 1.9; n = 2 | 0; n = 0 | 22.0 ± 39.7; n = 11 | 10.1 ± 8.6; n = 7 |
| SB5 | 12.6 ± NC; n = 1 | 0; n = 0 | 15.3 ± 13.7; n = 5 | 9.4 ± 4.9; n = 3 |
| GP2017 | 0; n = 0 | 3.6 ± 2.2; n = 2 | 8.4 ± NC; n = 1 | 0; n = 0 |
| FKB327 | 0; n = 0 | 8.0 ± NC; n = 1 | 0; n = 0 | 0; n = 0 |
| Golimumab | 16.3 ± 12.1; n = 21 | 19.3 ± 18.6; n = 7 | — | — |
| Tofacitinib | 13.4 ± 11.2; n = 8 | 4.0 ± NC; n = 3 | — | — |
| Vedolizumab | 20.2 ± 14.0; n = 37 | 17.1 ± 15.3; n = 25 | 18.9 ± 12.3; n = 21 | 20.2 ± 15.4; n = 16 |
| Ustekinumab | — | — | 12.8 ± 9.0; n = 20 | 12.1 ± 8.0; n = 23 |
Values are time in months, mean ± SD. Abbreviations: CD, Crohn’s disease; JAK, Janus kinase; NC, not calculable; UC, ulcerative colitis.